-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Small cell lung cancer (SCLC) is a highly aggressive type of lung cancer, accounting for approximately 15% of all newly diagnosed lung cancer cases
Small cell lung cancer (SCLC) is a highly aggressive type of lung cancer, accounting for approximately 15% of all newly diagnosed lung cancer cases
Among the 1305 patients included, most were male (n = 928, 68.
Among the 1305 patients included, most were male (n = 928, 68.
After excluding 4 patients lacking survival data, 1301 patients were included for survival analysis
PFS and OS
Multivariate analysis showed that female patients (HR = 0.
Multivariate analysis showed that female patients (HR = 0.
After adjusting for age, gender, body mass index, ECOG PS and other factors, the EP program is for overweight and obese patients (BMI ≥25 kg/m 2 ) PFS (hazard ratio [HR] = 0.
In the safety analysis, patients who received EC treatment experienced grade 3 AEs (n = 599, 74.
In summary, studies have shown that there is no significant difference between EC and EP regimens in the first-line treatment of patients with extensive-stage SCLC
Original source:
Original source:Jiang S, Huang L, Zhen H, Jin P, Wang J, Hu Z.
Jiang S, Huang L, Zhen H, Jin P, Wang J, Hu Z.
Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis.
BMC Cancer.
2021 Dec 7;21( 1):1308.
doi: 10.
1186/s12885-021-09034-6.
PMID: 34876060; PMCID: PMC8650295.
Leave a message here
